ARTHRITIS/
OSTEOPORISIS |
|
|
CANCER |
|
|
HEMATOLOGICAL DISORDERS/LEG ULCERS/ PITUITARY GLAND DISORDERS |
|
|
INFECTION |
|
|
NEUROLOGICAL DISORDERS/MIGRAINE |
|
|
PAIN |
|
|
RESPIRATORY DISEASES/DISORDERS |
|
SKIN DISORDERS
/DISEASES |
|
|
METHODOLOGICAL ISSUES |
|
|
ARTHRITIS/OSTEOPORISIS |
| |
Arthritis – Clinical Outcomes Studies |
|
PAR1 |
TREATMENT ADHERENCE WITH TNF-INHIBITORS AND METHOTREXATE IN PATIENTS
WITH RHEUMATOID ARTHRITIS IN A LARGE STATE MEDICAID PROGRAM
Singh G1, Mithal A2, Kavanaugh A3, 1Stanford University, Palo Alto, CA, USA;
2Institute for Clinical Outcomes Research and Education, Woodside, CA, USA;
3UCSD, La Jolla, CA, USA |
|
PAR2 |
TOWARDS VALUING
PREFERENCES FOR DISTRIBUTION OF HEALTH GAIN IN HIP AND KNEE DISEASE
Payne K, Davies L, Fargher E, Manchester University, Manchester, Gtr.
Manchester, United Kingdom |
|
|
Arthritis – Cost Studies |
|
PAR3 |
EVALUATING THE IMPACT OF
REIMBURSEMENT OF NON SELECTIVE COX2 INHIBITORS ON TOTAL DISPENSING OF
SELECTED NSAID AND SELECTED DRUGS FOR ACID RELATED
DISORDERS
Trindade R, Lourenço A, INFARMED, Lisbon, Portugal |
|
PAR4 |
ETANERCEPT VERSUS INFLIXIMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS:
A COST-EFFECTIVENESS ANALYSIS FROM THE ITALIAN NHS PERSPECTIVE
Lopatriello S, Berto P, PBE Consulting, Verona, Italy |
|
PAR5 |
THE TOTAL COSTS OF
TREATMENT WITH VALDECOXIB COMPARED TO GENERIC
DICLOFENAC ARE SIMILAR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN GERMANY
von Scheele B1, DePlatchett J1, Gaffney L2, Peña BM3, Niculescu L3, 1RTI
Health Solutions, Research Triangle Park, NC, USA; 2RTI Health Solutions,
Manchester, United Kingdom; 3Pfizer Inc, New York, NY, USA |
|
PAR6 |
ACUTE GOUTY ARTHRITIS: THE
COST-EFFECTIVENESS OF A NEW SELECTIVE COX-2 INHIBITOR (ETORICOXIB) IN THE UK
Martin M, Innovus Research, High Wycombe, United Kingdom |
|
PAR7 |
PHARMACOECONOMICS OF COX-2-SELECTIVE INHIBITORS VERSUS NON-SELECTIVE
NSAIDS AND CONCOMITANT COUMARIN USE: ECONOMIC EVALUATION LINKED TO A
CASE-CONTROL STUDY
Postma MJ1, Knijff-Dutmer EA2, van der Palen J2, van de Laar MA2, Brouwers
JR1, 1Groningen University Institute for Drug Exploration / University of
Groningen Research Institute of Pharmacy (GUIDE/GRIP), Groningen, The
Netherlands; 2Medisch Spectrum Twente (MST), Groningen, The Netherlands |
|
PAR8 |
AVERAGE DAILY DOSE AND
COSTS OF REIMBURSED COX-2 INHIBITORS FOR PATIENTS WITH RHEUMATOID ARTHRITIS
IN NORWAY
Sverre JM, Kristensen FK, PharmEcon AS, Asker, Norway |
|
PAR9 |
PATTERNS OF USE, DOSING AND ECONOMIC IMPACT OF
BIOLOGIC AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Gilbert TD, Smith D, Pedan A, Ollendorf D, PharMetrics Inc, Watertown, MA,
USA |
| |
|
|
|
Arthritis – Quality of Life Studies |
|
PAR10 |
CROSS-CULTURAL ADAPTATION
AND VALIDATION OF KOREAN VERSION OF EQ-5D IN PATIENTS WITH RHEUMATIC
DISEASES
Bae SC1, Kim MH2, 1Hanyang University, Seoul, South Korea; 2Eulji University
School of Medicine, Daejon, South Korea |
|
PAR11 |
IMPLEMENTATION STUDY OF A
HEALTH EDUCATION AND EXERCISE PROGRAM FOR OSTEOARTHRITIS OF THE KNEE
de Jong O, Hopman-Rock M, TNO Prevention and Health, Leiden, The Netherlands |
|
PAR12 |
ADAPTATION OF THE RAQOL FOR ESTONIA
Tammaru M1, McKenna SP2, Mottus E1, Maimets K1, 1University of Tartu, Tartu,
Estonia; 2Galen Research, Manchester, United Kingdom |
|
PAR13 |
UTILITY VALUATION FROM THE
PATIENT PERSPECTIVE OF TREATMENT OUTCOMES IN OSTEOARTHRITIS
Adams J1, Tilden DP2, Schulz M3, van Bavel J3, Mernagh P1, 1Medical
Technology Assessment Group, Chatswood West, NSW, Australia; 2Medical
Technology Assessment Group, Hammersmith, United Kingdom; 3Merck Sharpe &
Dohme (Australia) Pty Ltd, Granville, NSW, Australia |
| |
|
|
|
Osteoporosis – Cost Studies |
|
PAR14 |
THE COST OF OSTEOPOROTIC FRACTURES IN FEMALES IN THE UK: AN
EPIDEMIOLOGICAL MODEL
Jackson D1, Cockle SM1, Aristides M1, Sykes DP2, 1M-TAG Limited, London,
United Kingdom; 2Eli Lilly and Company, Windlesham, United Kingdom |
|
PAR15 |
THE BURDEN OF OSTEOPOROSIS
IN EUROPE: AN EPIDEMIOLOGICAL MODEL
Jackson D1, Cockle SM1, Aristides M1, Sykes DP2, 1M-TAG Limited, London,
United Kingdom; 2Eli Lilly and Company, Windlesham, United Kingdom
PAR16 AN ASSESSMENT OF THE ECONOMIC BURDEN OF BENZODIAZEPINE-ASSOCIATED
HOSPITAL TREATED FALL INJURIES IN THE EUROPEAN UNION
Panneman M1, Goettsch WG1, Kramarz P2, Herings RMC1, 1PHARMO Institute,
Utrecht, The Netherlands; 2Pfizer Pharmaceuticals Group, Warsaw, Poland |
|
PAR17 |
COST-EFFECTIVENESS OF
QUANTITATIVE ULTRASOUND AS A TECHNIQUE FOR SCREENING AND DIAGNOSING
OSTEOPOROSIS AND SUBSEQUENTLY FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES
Aidelsburger P1, Hessel FP2, Wasem J2, 1University of Greifswald, Greifswald,
Germany; 2University Duisburg-Essen, Essen, Germany |
|
PAR18 |
COST-EFFECTIVENESS
ANALYSIS OF DIFFERENT DRUG THERAPIES FOR OSTEOPOROSIS
Dzajkovska B, University of Ljubljana, Ljubljana, Slovenia |
| |
|
|
|
|
|
CANCER |
|
|
Cancer – Clinical Outcomes Studies |
|
PCN1 |
AN ASSESSMENT OF THE
UPDATED RESULTS FROM THE ARIMIDEX, TAMOXIFEN,
ALONE OR IN COMBINATION (ATAC) TRIAL: AN EVIDENCE-BASED MEDICINE APPROACH
Edwards SJ, AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom |
|
PCN2 |
BREAST CANCER PATIENTS'
USE OF HEALTH CARE INFORMATION IN DECISION-MAKING AND IN COPING WITH
ILLNESS: RESULTS OF A QUALITATIVE STUDY
Swaney J, Longo DR, Radina ME, University of Missouri-Columbia, Columbia,
MO, USA |
|
PCN3 |
EXPERT PANEL DEPICTION OF
CLINICAL PRACTICE IN THE TREATMENT OF BREAST CANCER PATIENTS IN GREECE
Pangali M1, Karokis A2, Gennatas K3, Makrantonakis P4, Markopoulos C5,
Pateras C6, Polychronis A7, Rigatos G8, Vasilios Skarlos D9, 1AstraZeneca,
Maroussi, Greece; 2AstraZeneca SA, Athens, Greece; 3Arteio Hospital, Athens,
Greece; 4Thegenion Cancer Institute, Thessaloniki, Greece; 5Laiko Hospital,
Athens, Greece; 6Apolonio Hospital, Athens, Greece; 76th IKA Hospital,
Athens, Greece; 8Saint Savvas Cancer Hospital, Athens, Greece; 9Henry Dunan
Hospital, Athens, Greece |
| |
|
|
|
Cancer – Cost Studies |
|
PCN4 |
ANALYSIS ON COST
DIFFERENCE BETWEEN DAILY FILGRASTIM AND ONCE PER CYCLE
PEGFILGRASTIM FOR PROPHYLAXIS AGAINST CHEMOTHERAPY-INDUCED NEUTROPENIA IN
FRANCE AND GERMANY
Suzcs TD1, Standaert B2, Lu ZJ3, 1University Hospital Basel, Basel,
Switzerland; 2Amgen Europe, Brussels, Belgium; 3Amgen Inc, Thousand Oaks,
CA, USA |
|
PCN5 |
REPORT ON RETROSPECTIVE
ANALYSIS OF HEALTH-CARE COSTS OF BONE FRACTURES IN WOMEN WITH EARLY STAGE
BREAST CANCER
Redaelli A1, Zhou Z2, Willke R2, Massimini G3, 1Pharmacia Corporation,
Milano, Italy; 2Pharmacia Corporation, Peapack, NJ, USA; 3Pharmacia
Corporation, Nerviano, Milano, Italy |
|
PCN6 |
HEALTH ECONOMIC EVALUATION
OF A NEW CONTRAST PRODUCT FOR LIVER MRI IN
COLORECTAL CANCER PATIENTS
Warie H1, Annemans L2, Mueller U3, 1HEDM, Meise, NA, Belgium; 2Ghent
University, HEDM, Meise, NA, Belgium; 3Schering AG, Berlin, Germany |
|
PCN7 |
ORAL VINORELBINE IN THE TREATMENT OF NON SMALL CELL LUNG CANCER
Le Lay K, Riou Franca L, Launois R, REES France, Paris, France |
|
PCN8 |
PHARMACO-ECONOMIC ASSESSMENT OF CAPECITABINE ORAL CHEMOTHERAPY VERSUS
FUFOL MAYO CLINIC CHEMOTHERAPY IN THE TREATMENT OF COLORECTAL CANCER
Omnes LF1, Woronoff Lemsi MC2, Foutel V3, 1Annie Chicoye Economics, Neuilly
Sur Seine, France; 2CHU Besançon, BESANÇON, France; 3F. Hoffmann-La Roche
Ltd, Basel, Switzerland |
|
PCN9 |
CHEMOTHERAPY-INDUCED
NAUSEA AND VOMITING (CINV) - OUTCOMES OF
PROPHYLACTIC CARE AND COSTS IN GERMAN CANCER CENTERS
Ehlken B1, Ihbe-Heffinger A2, Berger K1, Kugland B1, Lordick F3, Eichler
HG4, Deuson R4, Thödtmann J2, Bernard R2, 1MERG - Medical Economics Research
Group, Munich, Germany; 2Department of Pharmacy, Klinikum rechts der Isar,
Technische Universität München, München, Germany; 3III Medizinische Klinik
des Klinikums rechts der Isar, Technische Universität München, München,
Germany; 4Merck & Co. Inc, Whitehouse Station, NJ, USA |
| |
|
|
PCN10 |
COSTS OF MANAGING
TOXICITIES IN ADVANCED NON-SMALL CELL LUNG CANCER WITH PEMETREXED COMPARED WITH DOCETAXEL AS SECOND-LINE CHEMOTHERAPY
Aristides M1, Jackson D1, Liepa AM2, Leighl NB3, Shepherd F4, 1M-TAG
Limited, London, United Kingdom; 2Eli Lilly and Company, Indianapolis, IN,
USA; 3Princess Margaret Hospital/University Health Network, Toronto, ON,
Canada; 4University of Toronto, Toronto, ON, Canada |
|
PCN11 |
COMPARING THE PROVIDER
TIME AND COSTS FOR RED BLOOD CELL TRANSFUSIONS IN ANAEMIA MANAGEMENT OF CANCER PATIENTS USING THE ACTIVITY-BASED COSTING
(ABC) METHOD IN A FRENCH AND AUSTRIAN SETTING
Van Bellinghen L1, De Cock E2, Piedbois P3, Sevelda P4, Sevelda F4, 1Amgen
Health Economics Europe, Brussels, Belgium; 2MEDTAP International, London,
United Kingdom; 3CHU Henri Mondor, Créteil-Paris, France; 4Dept. of
Gynecology General Hospital Lainz, Vienna, Austria |
|
PCN12 |
BUDGET IMPACT ANALYSIS OF ANASTROZOLE AS ADJUVANT THERAPY IN THE
TREATMENT OF EARLY BREAST CANCER IN THE UK
Benedict Á1, Christie A2, 1MEDTAP International Inc, London, United Kingdom;
2AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom |
|
PCN13 |
COST-EFFECTIVENESS OF MOHS'MICROGRAPHIC SURGERY VERSUS SURGICAL
EXCISION FOR THE TREATMENT OF FACIAL BASAL CELL CARCINOMAS: RESULTS OF A
RANDOMISED CLINICAL TRIAL
Essers BAB1, Dirksen CD1, Smeets NWJV, Krekels GAM2, Nieman FHM2, Prins MH1,
Neuman HAM3, 1University Hospital Maastricht, Maastricht, The Netherlands;
2University Hospital Maastricht, Maastricht, Limburg, The Netherlands;
3University Hospital Rotterdam, Rotterdam, The Netherlands |
|
PCN14 |
COST IMPLICATIONS OF ORAL
TREATMENT OF COLORECTAL CANCER IN GERMANY
Hieke K1, Grothey A2, 1NEOS Health AG, Binningen, Switzerland; 2University
Hospital Halle, Halle, Germany |
| |
|
|
PCN15 |
COST ANALYSIS OF TREATMENT
FOR ADVANCED OR RECURRENT GASTRIC CANCER IN JAPAN: ECONOMIC COMPARISON
BETWEEN THE ORAL FLUOROPYRIMIDINE TS-1 AND
CONVENTIONAL INTRAVENOUS CHEMOTHERAPY
Sakamaki H1, Yajima S1, Ikeda S1, Ikegami N1, Tanaka K2, Murayama J2, 1Keio
University School of Medicine, Shinjuku-ku, Tokyo, Japan; 2Showa University
Hospital, Shinagawa-ku, Tokyo, Japan |
|
PCN16 |
HEAD AND NECK CANCER COSTS
IN A FRENCH PRIVATE CENTRE
Lafuma A1, Martin L2, Otero G3, Roossens JP3, 1CEMKA, Bourg la Reine,
France; 2Centre Guillaume le Conquérant, Le Havre, France; 3Echelon Local du
Havre du Service Médical de l’assurance Maladie, Le Havre, France |
|
PCN17 |
COST REDUCTION IN THE
DIAGNOSTIC EVALUATION OF PATIENTS WITH NON-SMALL CELL LUNG CANCER USING ENDOSCOPIC ULTRASONOGRAPHY WITH FINE-NEEDLE
ASPIRATION
Groen H, Post WJ, Groen HJM, Kramer H, TenVergert EM, Groningen University
Hospital, Groningen, The Netherlands |
|
PCN18 |
THE COST OF GEMCITABINE/CISPLATIN COMPARED WITH FOUR OTHER NOVEL
CHEMOTHERAPEUTIC AGENTS IN POLAND
Tilden D1, Stynes G1, Aristides M1, Lis J2, 1Medical Technology Assessment
Group, Hammersmith, United Kingdom; 2Eli Lilly Polska, Warsaw, Poland |
|
PCN19 |
COST ANALYSIS OF COMPLEXED PROSTATE SPECIFIC ANTIGEN IN THE DIAGNOSIS
OF PROSTATE CANCER
Warie H1, Annemans L2, Oosterlinck W3, 1HEDM, Meise, Belgium; 2Ghent
University, HEDM, Meise, Belgium; 3Ghent University, Ghent, Belgium |
| |
|
|
|
Cancer – Quality of Life Studies |
|
PCN20 |
PEGFILGRASTIM IS PREFERRED TO FILGRASTIM IN CANCER PATIENTS ON
MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT REGIMENS
Viens P1, Namer M2, Selle F3, 1Institut Paoli Calmettes, Marseille, France;
2Centre Antoine Lacassagne, Nice, France; 3Hôpital Tenon, Paris, France |
|
PCN21 |
COMPARISON OF PAIN
OUTCOMES AND HRQL USING THE TREATMENT OUTCOMES IN
PAIN SURVEY (TOPS) IN CANCER-RELATED PAIN
Orkin FK1, Polomano RC1, Burton AW2, Gordin V1, Rathmell JP3, Carr DB4,
1Penn State University, Hershey, PA, USA; 2Univ of Texas MD Anderson Cancer
Center, Houston, TX, USA; 3Fletcher-Allen Health Care, Burlington, VT, USA;
4Tufts University, Boston, MA, USA |
|
|
|
|
HEMATOLOGICAL DISORDERS/LEG ULCERS/ PITUITARY GLAND DISORDERS |
|
|
Hematological Disorders & Leg Ulcers – Clinical Outcomes Studies |
|
PHL1 |
HEMOGLOBIN LEVELS ASSOCIATED WITH DIAGNOSIS OF
ANEMIA
Lawless GD1, Barron JJ2, Willey VJ2, Tannous RE1, Daniel GW2, 1Amgen, Inc,
Thousand Oaks, CA, USA; 2Health Core, Inc, Newark, DE, USA |
|
PHL2 |
PROBABILITY OF INITIATING ERYTHROPOIETIC THERAPY
Lawless GD1, Barron JJ2, Willey VJ2, Tannous RE1, Daniel GW2, 1Amgen, Inc,
Thousand Oaks, CA, USA; 2Health Core, Inc, Newark, DE, USA |
| |
|
|
|
Hematological Disorders & Leg Ulcers – Cost Studies |
|
PHL3 |
COST-EFFECTIVENESS OF HAEMOPHILIA TREATMENT: A CROSS-NATIONAL
ASSESSMENT
Schramm B1, Berger K1, Siebert U2, Berntorp E3, Giangrande P4, van den Berg
M5, Schramm W1, 1Ludwig-Maximilians-University, München, Germany; 2Harvard
School of Public Health, Boston, MA, USA; 3Malmö University Hospital, Malmö,
Sweden; 4Churchill Hospital, Oxford, United Kingdom; 5University Medical
Centre, Van Creveldkliniek, Utrecht, The Netherlands |
|
PHL4 |
COST OF CARE AND QUALITY
OF LIFE IN HEMOPHILIACS DEVELOPING INHIBITORS AGAINST PRODUCTS OF
COAGULATION: THE COCIS STUDY
Scalone L1, Gringeri A2, Mannucci PM2, Mantovani LG1, 1University of Milan,
Milan, Italy; 2IRCCS Maggiore Hospital and University of Milan, Milan, Italy |
|
PHL5 |
HEALTH ECONOMIC ANALYSIS
OF A SILVER CONTAINING HYDROACTIVATED FOAM
DRESSING IN DELAYED HEALING LEG ULCERS
Scanlon E1, Poulsen PB2, Christensen TL2, Karlsmark T3, Leaper D4, Ballard
K5, Hahn TW6, Hart-Hansen K6, 1St. Mary's House, Leeds, United Kingdom;
2MUUSMANN Research & Consulting, Kolding, Denmark; 3Bispebjerg University
Hospital, Copenhagen NV, Denmark; 4University Hospital of North Tees,
Stockton on Tees, United Kingdom; 5Guy's Hospital, London, United Kingdom;
6Coloplast A/S, Humlebaek, Denmark |
|
PHL6 |
TREATMENT OF LEG ULCERS IN
SWEDEN STILL DEMANDS LARGE RESOURCES IN SPITE OF IMPROVED MANAGEMENT - THE
COST OF ILLNESS (COI) ESTIMATED FROM A
PATIENT SURVEY AND PUBLISHED EPIDEMIOLOGICAL STUDIES
Ragnarson Tennvall G, Hjelmgren J, IHE, Lund, Sweden |
|
PHL7 |
COST OF TREATMENT (COT)
FOR VENOUS LEG ULCERS IN SWEDEN AND THE UK - ESTIMATES FROM CLINICAL EXPERT
PANELS AND MODEL SIMULATIONS
Ragnarson Tennvall G, Hjelmgren J, IHE, Lund, Sweden |
|
PHL8 |
COST-EFFECTIVENESS OF
PATHOGEN INACTIVATION VIA THE INTERCEPT BLOOD SYSTEM FOR PLATELETS IN SPAIN
García de Villaescusa Collazo R1, Barallobre J2, Staginnus U2, 1Centro de
Transfusión de la Comunidad de Madrid, Madrid, Spain; 2Baxter, S.L, Madrid,
Spain |
| |
|
|
|
Hematological Disorders & Leg Ulcers– Quality of Life Studies |
|
PHL9 |
APPLICATION OF CONJOINT
ANALYSIS TO ELICIT PREFERENCES IN HEMOPHILIA CARE: THE CONAN STUDY GROUP
Monzini MS1, Gringeri A2, Scalone L1, Busca R3, Mannucci PM2, Mantovani LG1,
1University of Milan, Milan, Italy; 2IRCCS Maggiore Hospital and University
of Milan, Milan, Italy; 3Bayer, Milan, Italy |
|
PHL10 |
ASSESSING PATIENT
PREFERENCES AND QUALITY-ADJUSTED LIFE YEARS (QALY)
OF PROPHYLACTIC HAEMOPHILIA TREATMENT
Schramm B1, Berger K1, Siebert U2, Berntorp E3, Giangrande P4, van den Berg
M5, Schramm W1, 1Ludwig-Maximilians-University, München, Germany; 2Harvard
School of Public Health, Boston, MA, USA; 3Malmö University Hospital, Malmö,
Sweden; 4Churchill Hospital, Oxford, United Kingdom; 5University Medical
Centre, Van Creveldkliniek, Utrecht, The Netherlands |
|
PHL11 |
DEVELOPMENT OF THE HAEMOPHILIA AGE-GROUP SPECIFIC QUALITY OF LIFE
QUESTIONNAIRE
Trudeau E1, Dias C1, Lambert T2, Chambost H3, Peynet J4, Fressinaud E5,
Guerois C6, 1Mapi Values, LYON, France; 2CHU Bicetre, Kremlin Bicetre,
France; 3CHU Timone, Marseille, France; 4CTS, Le Chesnay, France; 5CHU Hotel
Dieu, Nantes, France; 6CHU Hopital Trouseau, Tours, France |
|
|
Pituitary Gland Disorders – Cost Studies |
|
PHL12 |
MORE PRECISE DOSING
INCREMENTS OF HUMAN GROWTH HORMONE DELIVERY SYSTEMS LEAD TO COST SAVINGS IN
THE UK SETTING
Lammert M, Roze S, Lurati FM, Valentine WJ, Palmer AJ, CORE Center for
Outcomes Research, Binningen, Basel, Switzerland |
|
|
Pituitary Gland Disorders – Quality of Life Studies |
|
PHL13 |
THE USE OF A
CONDITION-SPECIFIC QUALITY OF LIFE MEASURE (QUALITY OF LIFE – ASSESSMENT FOR
GROWTH HORMONE DEFICIENCY IN ADULTS) IN A GENERAL POPULATION
Kind P1, Hennessy S1, Koltowska M2, 1University of York, York, United
Kingdom; 2KIGS/KIMS Outcomes Research, Pharmacia AB, Stockholm, Sweden |
| |
|
|
|
|
|
INFECTION |
|
|
Infection – Clinical Outcomes Studies |
|
PIN1 |
PHARMACEUTICAL MANAGEMENT
OF NEWLY HIV+ DIAGNOSED PATIENTS: RESULTS FROM THE STAR (SCHEMAS THERAPEUTIQUES-ANTIRETROVIRAUX) COHORT
Lilliu H1, Raffi F2, Massip P3, Rozenbaum W4, Maurel F1, Foucher F5, Durand
I5, Priol G1, Vincensini JP4, Bugnon F2, Delpierre C3, Le Pen C1,
1Clp-santé, Paris, France; 2CHRU Nantes, Hotel Dieu, Nantes Cedex 1, France;
3CHU Toulouse Hôpital Purpan, Toulouse, France; 4Hopital Tenon, Paris,
France; 5GlaxoSmithKline, Marly Le Roy, France |
|
PIN2 |
ASSOCIATION BETWEEN
UNSUCCESSFUL INITIAL EMPIRIC ANTIBIOTIC THERAPY AND HEALTH CARE RESOURCE USE
AMONG PATIENTS UNDERGOING SURGERY FOR COMMUNITY-ACQUIRED INTRA-ABDOMINAL
INFECTIONS IN SPAIN
Sen SS1, Geling O1, Gonzalez TC2, Nocea Pulfer G2, 1Merck & Co., Inc,
Whitehouse Station, NJ, USA; 2Merck Sharp & Dohme, Spain, Madrid, Spain |
|
PIN3 |
ASSOCIATION BETWEEN SKIN TATOOS AND HEPATITIS B OF 1/2000 PRIVATES AT
ADISORN FORT HOSPITAL, THAIALND
Auamnoy T, Mekaroonreung S, Taweechoitipatr P, Auamnoy T, Chulalongkorn
University, Bangkok, Thailand |
|
PIN4 |
CONSUMPTION OF ANTIBIOTICS
IN EUROPE: RESULTS OF THE ESAC RETROSPECTIVE
DATA COLLECTION
Ferech M, Elseviers M, Vander Stichele R, Goossens H, ESAC Management Team,
University of Antwerp, Antwerp, Belgium |
|
PIN5 |
REGIONAL ANTIBIOTIC
PRESCRIBING GUIDELINE ADHERENCE RESULTS
Fazio J1, Haase M2, Sasaki P2, 1Northwest Pharmacy Services, Portland, OR,
USA; 2Strong Square, LLC, Kirkland, WA, USA |
|
PIN6 |
INDICATORS OF ANTIBIOTIC
USE IN PRIMARY HEALTH CARE OF REPUBLIC OF SRPSKA
Tasic L1, Vucen M2, 1Faculty of Pharmacy, University of Belgrade, Belgrade,
Yugoslavia; 2Community Pharmacy Chain Banja Luka, Republic of Srpska, Bosnia |
|
PIN7 |
AN ANALYSIS OF IN-VITRO UROPATHOGEN SENSITIVITY DATA TO UPDATE THE
GUIDELINES FOR THE EMPIRIC TREATMENT OF UNCOMPLICATED URINARY TRACT
INFECTION IN ADULT WOMEN IN A MANAGED CARE SETTING
Blackman S1, Waitman DA2, Kahan NR3, Bar-Yochai A4, 1Leumit Health Fund,
Petah Tikvah, Israel; 2Leumit Health Fund, Tel Aviv, Israel; 3Leumit Health
Fund, Petah Tikvah, Israel; 4Assaf Harofeh Medical Centre, Be'er Ya'acov,
Israel |
| |
|
|
|
Infection – Cost Studies |
|
PIN8 |
PROSPECTIVE STUDY ON ACUTE
LOWER RESPIRATORY TRACT INFECTIONS IN GERMAN CHILDREN YOUNGER THAN 3 YEARS (PRI.DE) - ECONOMIC IMPACT OF HOSPITALIZED
CASES
Ehlken B1, Berger K1, Ihorst G2, Petersen G3, Forster J4, 1MERG - Medical
Economics Research Group, Munich, Germany; 2Institute of Medical Statistics,
University Freiburg, Freiburg, Germany; 3Wyeth, Münster, Germany; 4St.
Josefskrankenhaus and University Children's Hospital Freiburg, Freiburg,
Germany |
|
PIN9 |
COST-EFFECTIVENESS OF TWO
DIFFERENT VACCINATION STRATEGIES FOR THE PREVENTION OF MENINGOCOCCAL C
DISEASE IN PORTUGAL
Silverio N, Teixeira Brandao J, Chinopa P, Wyeth Lederle Portugal, Alges,
Portugal |
|
PIN10 |
A COST CONSEQUENCE ON
CONCOMITANT DRUG USE DURING HCV THERAPY IN
MANAGED CARE PATIENTS IN THE UNITED STATES
Le TK, Yu H, TIER, Bridgewater, NJ, USA |
|
PIN11 |
ABACAVIR HYPERSENSITIVITY: IS PRE-PRESCRIPTION GENOTYPING
COST-EFFECTIVE?
Hughes DA, Pirmohamed M , University of Liverpool, Liverpool, United Kingdom |
|
PIN13 |
COST-EFFECTIVENESS OF VORICONAZOLE COMPARED WITH CONVENTIONAL
AMPHOTERICIN B IN FIRST LINE TREATMENT OF INVASIVE ASPERGILLOSIS IN BELGIUM
Marbaix S1, Marciniak A2, De Mees V1, Aoun M3, 1Pfizer s.a, Brussels,
Brabant, Belgium; 2Pfizer UK, Sandwich, Kent, United Kingdom; 3Institut
Jules Bordet, Brussels, Brabant, Belgium |
|
PIN14 |
POST-EXPOSURE INFLUENZA
PROPHYLAXIS WITH OSELTAMIVIR:
COST-EFFECTIVENESS AND COST-UTILITY IN FAMILIES IN THE UK
Sander B1, Gyldmark M2, Bergemann R2, Garrison L2, 1Institute for Medical
Outcome Research (IMOR), Loerrach, Germany; 2F. Hoffman-La Roche Ltd, Basel,
Switzerland |
| |
|
|
PIN15 |
COST-EFFECTIVENESS
ANALYSIS OF VORICONAZOLE VERSUS AMPHOTERICIN B IN
THE TREATMENT OF INVASIVE ASPERGILLOSIS IN SPAIN
Grau S1, Mateu-de Antonio J1, Soto J2, Muñoz M2, Salas E1, 1Hospital del
Mar, Barcelona, Spain; 2Pfizer, S.A, Alcobendas, Madrid, Spain |
|
PIN16 |
COST-EFFECTIVENESS
ANALYSIS OF FUZEON ADDED TO OPTIMAL STANDARD
THERAPY VS. OPTIMIZED BACKGROUND REGIMEN ALONE IN PATIENTS WITH HIV/AIDS
Serrano D1, Magaz S1, Badia X2, Alvarez C3, Green J4, 1Health Outcomes
Policy And Economics, Barcelona, Spain; 2Health Outcomes Research Europe
Group, Barcelona, Spain; 3Roche Farma S.A, Madrid, Spain; 4Hoffmann-La Roche
Inc, Nutley, NJ, USA |
|
PIN17 |
COSTS OF
COMMUNITY-ACQUIRED PNEUMONIA FROM THE HOSPITAL’S PERSPECTIVE IN GERMANY – A
PROSPECTIVE OBSERVATIONAL STUDY
Bauer TT1, Schlosser BM1, Ernen C2, Thate-Waschke IM3, Pfeil T2, Daniel D4,
Rychlik R2, 1Bergmannsheil Hospital, University of Bochum, Bochum, Germany;
2Institute of Empirical Health Economics, Burscheid, Germany; 3Bayer Vital
GmbH, Germany, Leverkusen, Germany; 4Institute of Empirical Health
Economics, Bochum, Germany |
|
PIN18 |
PROJECTED CLINICAL
BENEFITS AND COST-EFFECTIVENESS OF AN HPV 16/18
VACCINE
Goldie SJ1, Kohli MA2, Grima D2, Weinstein MC1, Wright TC3, Bosch FX4,
Franco EL5, 1Harvard School of Public Health, Boston, MA, USA; 2Innovus
Research Inc, Burlington, ON, Canada; 3Columbia University School of
Medicine, New York, NY, USA; 4Institut Catala d'Oncologia, Barcelona, Spain;
5McGill University, Montreal, QC, Canada |
|
PIN19 |
ECONOMIC IMPACT OF
ANTIRETROVIRAL DRUG PRICE REDUCTIONS IN NINE LATIN AMERICAN COUNTRIES
Becker R, Hill J, Ovation Research Group, Highland Park, IL, USA |
|
PIN20 |
THE IMPACT OF
COST-EFFECTIVENESS OF COUNTRY SPECIFIC APPLICATION - THE CASE OF DROTRECOGIN ALFA (ACTIVATED) IN SEVERE SEPSIS
Persson U1, Hjelmgren J1, Ragnarson Tennvall G1, Davies A2, 1IHE, Lund,
Sweden; 2Medtap International, London, United Kingdom |
| |
|
|
PIN21 |
BUDGET IMPACT ANALYSIS OF
UNIVERSAL VARICELLA VACCINATION IN GERMANY
Hammerschmidt T1, Banz K2, Goertz A1, Wagenpfeil S3, Neiss A3, Wutzler P4,
1GlaxoSmithKline, Munich, Germany; 2Outcomes International, Basel,
Switzerland; 3Technical University Munich, Munich, Germany;
4Friedrich-Schiller-University, Jena, Germany |
|
PIN22 |
MODELLING THE COST-EFFECTIVENESS OF THE VARICELLA VACCINE IN PORTUGAL
Portugal-Fernandes R, Andrea B, The University of North Carolina at Chapel
Hill, Chapel Hill, NC, USA |
|
PIN23 |
SPANISH HEALTH
INTERVENTIONS FOR CHRONIC HEPATITIS B AND THEIR ASSOCIATED COSTS
Antonanzas F1, Velasco M2, Yanguela J3, Iloeje U4, 1University of La Rioja,
Logrono, Spain; 2SOIKOS, Barcelona, Spain; 3Hospital San Millan-San Pedro,
Logrono, Spain; 4Bristol-Myers Squibb, Wallingford, CT, USA |
|
PIN24 |
THE COST-EFFECTIVENESS OF
23-VALENT PNEUMOCOCCAL VACCINE IN CATALONIA,
SPAIN
Plans-Rubió P, Departament de Sanitat of Catalonia, Barcelona, Spain |
|
PIN25 |
COST-EFFECTIVENESS OF A
PHARMACY-BASED SCREENING FOR CHLAMYDIA TRACHOMATIS
van Bergen JE1, Postma MJ2, Peerbooms PG3, Spangenberg AC4, Tjen-A-Tak J5,
Bindels PJ5, 1Foundation for STI-control, Utrecht, The Netherlands;
2Groningen University Institute for Drug Exploration/ University of
Groningen Research Institute of Pharmacy (GUIDE/GRIP), Groningen, The
Netherlands; 3Municipal Regional Public Health Laboratory, Amsterdam, The
Netherlands; 4Health Centre Venserpolder, Groningen, The Netherlands;
5Academic Medical Centre, Amsterdam, The Netherlands |
|
PIN26 |
COST OF MANAGING CHRONIC
HEPATITIS B IN THE UK
Brown R1, De Cock E1, Iloeje U2, 1MEDTAP International, London, United
Kingdom; 2Bristol-Myers Squibb, Wallingford, CT, USA |
|
PIN27 |
COST-EFFECTIVENESS AND
VALUE OF INFORMATION ANALYSES OF THE USE OF ANTIVIRALS FOR THE TREATMENT OF INFLUENZA IN HEALTHY ADULTS
Wailoo AJ1, Turner D2, Cooper N2, Sutton A2, Abrams K2, Nicholson K2,
1University of Sheffield, Sheffield, United Kingdom; 2Leicester University,
Leicester, United Kingdom |
| |
|
|
PIN28 |
HOSPITAL MANAGEMENT OF PERTUSSIS IN GERMANY: COST PER CASE BY AGE
O'Brien JA, Pitoniak-Morse CA, Caro J, Caro Research Institute, Concord, MA,
USA |
|
PIN29 |
REDUCING INFLUENZA
SYMPTOMS BY 1.5 DAYSA PROSPECTIVE RANDOMIZED TRIAL
USING THE CONTINGENT VALUATION METHOD TO ELICIT PREFERENCES FOR
NEURAMINIDASE INHIBITORS
von Bremen KK, Martin E, Holly A, Paccaud F, University of Lausanne
Switzerland, Lausanne, Switzerland |
|
PIN30 |
COSTS OF PULMONARY
TUBERCULOSIS IN UKRAINE
Zaliska ON, Yanishyn UY, Lviv Medical University, Lviv, Ukraine |
|
PIN31 |
COST-EFFECTIVENESS
ANALYSIS OF ONCE-DAILY MODIFIED RELEASE CLARITHROMYCIN VERSUS CONVENTIONAL TWICE-DAILY GENERIC CLARITHROMYCIN FOR
THE TREATMENT OF RESPIRATORY TRACT INFECTIONS
Rubio M1, Magaz S1, Badia X2, 1Health Outcomes Policy and Economics,
Barcelona, Spain; 2Health Outcomes Research Europe Group, Barcelona, Spain |
|
PIN32 |
THE POTENTIAL
EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF A NEW COMBINATION VACCINE AGAINST
MENINGOCOCCAL B AND C AND PNEUMOCOCCAL INFECTIONS IN THE
NETHERLANDS
Bos JM1, Rümke HC2, Welte R3, Postma MJ4, van Alphen L5, 1The Netherlands
Vaccine Institute, Bilthoven, The Netherlands/Groningen University Institute
for Drug Exploration, Groningen, The Netherlands; 2Vaccine Centre of the
Erasmus University, Rotterdam, The Netherlands; 3University of Ulm, Ulm,
Germany; 4Groningen University Institute for Drug Exploration / University
of Groningen Research Institute of Pharmacy (GUIDE/GRIP), Groningen, The
Netherlands; 5The Netherlands Vaccine Institute, Bilthoven, The Netherlands |
|
PIN33 |
COST-EFFECTIVENESS OF
DIFFERENT TREATMENT STRATEGIES WITH INTRAPARTUM
ANTIBIOTIC PROPHYLAXIS TO PREVENT EARLY-ONSET GROUP B STREPTOCOCCAL DISEASE
van den Akker E, Rijnders M, van Dommelen P, TNO Preventie en Gezondheid,
Leiden, Zuid Holland, The Netherlands |
|
PIN34 |
COST-EFFECTIVENESS OF TWO
SCREENING STRATEGIES FOR CHLAMYDIA TRACHOMATIS INFECTIONS IN FRANCE
Préaubert N, Delaveyne R, ANAES, Saint Denis la Plaine, Cedex, France |
| |
|
|
PIN35 |
MENINGOCOCCAL C
VACCINATION OF CHILDREN AGED LESS THAN 1 YEAR: INCLUSION OF HERD IMMUNITY
LEADS TO LESS FAVORABLE COST-EFFECTIVENESS RATIOS
Welte R1, van den Dobbelsteen G2, Postma MJ3, 1University of Ulm, Ulm,
Germany; 2National Institute of Public Health and the Environment, Bilthoven,
The Netherlands; 3Groningen University Institute for Drug Exploration /
University of Groningen Research Institute of Pharmacy (GUIDE/GRIP),
Groningen, The Netherlands |
|
PIN36 |
COST-EFFECTIVENESS OF
RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS
AMONG PRETERM INFANTS IN POLAND
Kowalik E1, Jakubczyk MK1, Niewada MP2, Kamiñski B1, 1Warsaw School of
Economics, Warsaw, Poland; 2Medical University of Warsaw, Warsaw, Poland |
|
PIN37 |
INTRODUCTION OF A NEW
HEALTH TECHNOLOGY, POTENTIAL BEHAVIOURAL AND
ORGANIZATIONAL CHANGES AND POLICY IMPACT - ASSESSMENT OF NEW INFLUENZA
TREATMENTS
Gyldmark M1, Sander B2, 1F. Hoffman-La Roche Ltd, Basel, Switzerland;
2Institute for Medical Outcome Research, Loerrach, Germany |
|
PIN38 |
COST-EFFECTIVENESS
ANALYSIS OF PEGYLATED INTERFERONS COMBINED WITH
RIBAVIRIN IN THE TREATMENT OF HEPATITIS C
Mar J1, Antonanzas F2, Velasco M3, Bendeck M3, Sola R4, Planas R5, Alvarez
C6, Hospital Alto Deba, Mondragon, Guipuzcoa, Spain; 2University of La Rioja,
Logroño, Spain; 3Soikos, Barcelona, Barcelona, Spain; 4Hospital del Mar,
Barcelona, Spain; 5Hospital Germans Trias y Pujol, Badalona, Barcelona,
Spain; 6Roche Farma S.A, Madrid, Spain |
|
PIN39 |
DIRECT COST ANALYSIS OF
HEPATITIS B INFECTION IN FRANCE
Colin X1, Fagnani F1, Iloeje U2, 1CEMKA, Bourg la Reine, France;
2Bristol-Myers Squibb, Wallingford, CT, USA |
| |
|
|
|
Infection – Quality of Life Studies |
|
PIN40 |
PREVALENCE AND QUALITY OF
LIFE OF PATIENTS SUFFERING FROM HERPES LABIALIS WITH IN FRANCE – INSTANT STUDY
Stalder JF1, Crochard A2, Mimaud V3, Wolkenstein P4, Lorette G5, El Hasnaoui
A6, 1Hôtel Dieu Hospital, Nantes, France; 2GlaxoSmithKline, Marly Le Roy,
France; 3CEMKA, Bourg la Reine, France; 4Henri Mondor Hospital, Créteil,
France; 5Trousseau Hospital, Tours, France; 6laboratory GSK, Marly Le Roy,
France |
|
PIN41 |
DEVELOPMENT OF THE HERPES
OUTBREAK IMPACT QUESTIONNAIRE (HOIQ)
Doward LC, McKenna SP, Meads DM, Galen Research, Manchester, United Kingdom |
|
PIN42 |
MEASURING
TREATMENT-SPECIFIC ASPECTS OF HRQL IN PATIENTS SUFFERING
FROM PRIMARY ANTIBODY DEFICIENCIES
Nicolay U1, Hoegy B2, Reitberger U3, Gardulf A4, 1Covidence GmbH, Marburg,
Germany; 2Aventis Behring GmbH, Marburg, Germany; 3Kendle International Inc,
Munich, Germany; 4Huddinge University Hospital, Stockholm, Sweden |
| |
|
|
|
|
|
NEUROLOGICAL DISORDERS/MIGRAINE |
|
|
Neurological Disorders/Migraine – Clinical Outcomes Studies |
|
PNM1 |
CARE OF PARKINSON'S
DISEASE PATIENTS IN EUROPEAN COUNTRIES; EUROPEAN COOPERATIVE NETWORK FOR
RESEARCH, DIAGNOSIS AND, THERAPY OF PARKINSON'S DISEASE (EUROPA)
v. Campenhausen S1, Berger K2, Dodel R1, Wick R3, Oertel WH3,
1Friedrich-Wilhelms-University, Bonn, Germany; 2MERG Medical Economics
Research Group, Munich, Germany; 3Phillips-University, Marburg, Germany |
|
|
Neurological Disorders/Migraine – Cost Studies |
|
PNM2 |
COST-EFFECTIVENESS OF ELETRIPTAN 40MG COMPARED WITH STANDARD DOSES OF
AVAILABLE TRIPTANS FOR ACUTE MIGRAINE ATTACKS IN SPAIN
Gracia-Naya M1, Rejas J2, León T3, 1Department of Neurology, Hospital Miguel
Servet, Zaragoza, Spain; 2Health Outcomes Research, Medical Unit, Pfizer SA,
Alcobendas, Madrid, Spain; 3Medical Unit, Pfizer Spain SA, Alcobendas,
Madrid, Spain |
|
PNM3 |
A COST EFFECTIVENESS
ANALYSIS OF ZOLMITRIPTAN NASAL SPRAY
Annemans L1, Warie H2, Vanlerberghe T3, 1Ghent University, HEDM, Meise,
Belgium; 2HEDM, Meise, Belgium; 3AstraZeneca, Brussels, Belgium |
|
PNM4 |
COST-EFFECTIVENESS STUDY
OF RIZATRIPTAN VS. USUAL CARE IN THE TREATMENT
OF MIGRAINE IN CANADA
Desjardins B1, Thompson M2, Ferko N2, Marceau C1, Gawel M3, 1Merck Frosst
Canada Ltd, Kirkland, QC, Canada; 2Innovus Research Inc, Burlington, ON,
Canada; 3University of Toronto; Sunnybrook and Women's College Health
Sciences center, Toronto, ON, Canada |
|
PNM5 |
MANAGEMENT COSTS OF CHEST AND CNS-RELATED ADVERSE EVENTS OF TRIPTANS
(SEROTONIN 5-HT1B/1D AGONISTS) IN SPAIN
Slof J1, Magaz S1, Badia X2, Láinez M3, Galván J4, 1Health Outcomes Policy &
Economics, Barcelona, Spain; 2Health Outcomes Research Europe Group,
Barcelona, Spain; 3Hospital Clínico Universitario, Universidad De Valencia,
Valencia, Spain; 4Almirall Prodesfarma, Barcelona, Spain |
| |
|
|
PNM6 |
INDIRECT COSTS DUE TO
MIGRAINE IN THE UNITED STATES
Mychaskiw MA, Sankaranarayanan J, Heenan P, Purdue University, West
Lafayette, IN, USA |
|
PNM7 |
A COST-EFFECTIVENESS
ANALYSIS OF ELETRIPTAN 40MG AND 80MG VERSUS
SUMATRIPTAN 50MG AND 100MG IN THE ACUTE TREATMENT OF MIGRAINE
Wells NEJ1, Drummond M2, 1Pfizer Global Research and Development, Sandwich,
Kent, United Kingdom; 2Innovus Research (UK) Ltd., and University of York,
York, United Kingdom |
|
PNM8 |
ALZHEIMER’S DISEASE COST
OF TREATMENT STUDY (ADCOT) IN THE UNITED
KINGDOM
Evans M1, Squires N2, Yuen C2, 1Clatterbridge Hospital, Wirral, United
Kingdom; 2Janssen-Cilag Ltd, Buckinghamshire, United Kingdom |
|
PNM9 |
TIME SPENT AND COST ON
INFORMAL CARE GIVING FOR PERSONS WITH ALZHEIMER IN SPAIN
Lopez Bastida J, Serrano Aguilar P, Yanes Lopez V, Duque González B,
Canarian Health Service, Santa Cruz de Tenerife, S/C de Tenerife, Spain. |
|
PNM10 |
COST EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATELY SEVERE
AND SEVERE ALZHEIMER’S DISEASE IN SPAIN
Antonanzas F1, Badenas J2, François C3, Guilhaume C3, 1University of La
Rioja, Logroño, Logroño, Spain; 2H. Lundbeck A/S, Barcelona, Spain; 3H. Lundbeck A/S, Paris, France |
|
PNM11 |
IMPACT OF DEEP BRAIN
STIMULATION (DBS) OF THE SUBTHALAMIC NUCLEUS (STN)
ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH CARE RESOURCE USE IN
ADVANCED PARKINSONIAN PATIENTS
Maurel F1, Ligier M2, Le Pen C2, Pollak P3, 1CLP Santé, Paris, France;
2CLP-Santé, Paris, France; 3The French Spark Study Group, Grenoble, France |
| |
|
|
PNM12 |
EARLY DECISION MAKING MODELLING IN PARKINSON’S DISEASE–THE CASE OF
NEURAL TRANSPLANTATION IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE
Hjelmgren J1, Reimer J2, Persson U1, Ghatnekar O1, Gabrowski M2, Lindvall
O2, Hagell P2, 1IHE, Lund, Sweden; 2Lund University Hospital, Lund, Sweden |
|
PNM13 |
ECONOMIC EVALUATION OF DATSCAN IN THE DIAGNOSIS OF PARKINSONISM
Annemans L1, Chambers M2, 1Ghent University, HEDM, Meise, Belgium; 2Amersham
Health, Bucks, United Kingdom |
|
PNM14 |
SOCIO-ECONOMIC IMPACT OF
EPILEPSY ON PARENTS: THE TRILOGY STUDY
Brun - Strang C1, Plouin P2, 1Novartis-Pharma, Rueil-Malmaison, France;
2Hôpital St Vincent de Paul, Paris, France |
|
PNM15 |
DO PEOPLE CONSIDER THE
EFFECTS OF ILL-HEALTH ON INCOME AND LEISURE WHEN ANSWERING HEALTH-RELATED
QUALITY-OF-LIFE QUESTIONS?
Sendi P1, Brouwer WBF2, 1Basel University Hospital, Basel, Switzerland;
2Erasmus University Rotterdam, Rotterdam, The Netherlands |
|
PNM16 |
THE COSTS OF MULTIPLE
SCLEROSIS - A CROSS-SECTIONAL PROSPECTIVE
MULTI-CENTRE COST OF ILLNESS STUDY IN POLAND
Orlewska E1, Mierzejewski P1, Zaborski J2, Czlonkowska A2, 1Medical
University of Warsaw, Warsaw, Poland; 2Institute of Psychiatry and
Neurology, Warsaw, Poland |
|
PNM17 |
RETROSPECTIVE EVALUATION
OF THE DOSE OF DYSPORT® AND BOTOX® IN THE CLINICAL MANAGEMENT OF CERVICAL
DYSTONIA OR BLEPHAROSPASM - COST CONSIDERATIONS FOR THE REAL DOSE STUDY
Marchetti A1, Magar R1, Ahmed F2, Findley L3, Larsen JP4, Pirtosek
Z5, Ruzicka E6, Slawek J7, 1Thomson Health Economics Research, Secaucus, NJ,
USA; 2Hull Royal Infirmary, Hull, United Kingdom; 3Avenue House, Romford,
United Kingdom; 4Central Hospital of Rogaland, Stavanger, Norway;
5University Clinical Centre,
Ljubljana 1525, Slovenia; 6Movement Disorder Center, Prague 2, Czech
Republic; 7St Adalbert Hospital, Gdansk, Poland |
|
PNM18 |
COST-EFFECTIVENESS OF Z
DRUGS (ZOLPIDEM, ZOPICLONE AND ZALEPLON) VERSUS BENZODIAZEPINES FOR THE
SHORT–TERM MANAGEMENT OF INSOMNIA: A SYSTEMATIC LITERATURE REVIEW
Boland A, Haycox A, Dundar Y, Dickson R, Walley T, University of Liverpool,
Liverpool, United Kingdom |
|
PNM19 |
RESOURCE UTILISATION AND
COSTS OF PATIENTS WITH SPINAL CORD INJURY (SCI) AFTER INITIAL REHABILITATION
Hieke K1, Hoser H2, 1NEOS Health AG, Binningen, Switzerland;
2Berufsgenossenschaftliche Unfallklinik Hamburg, Germany, Hamburg, Germany
|
| |
|
|
|
Neurological
Disorders/Migraine – Quality of Life Studies |
|
PNM20 |
VALIDATION OF SINGAPOREAN
ENGLISH AND CHINESE EQ-5D VERSIONS IN PATIENTS WITH PARKINSON’S DISEASE
Luo N1, Tan LCS2, Li SC1, Thumboo J3, 1National University of Singapore,
Singapore, Singapore; 2National Neuroscience Institute, Singapore,
Singapore; 3Singapore General Hospital, Singapore, Singapore |
|
PNM21 |
PIRIBEDIL IMPROVES QUALITY
OF LIFE IN PATIENTS WITH PARKINSON’S DISEASE IN RUSSIA
Chikina ES1, Guekht AB2, Gusev EI1, Belousov YB1, Gluchkov KS1, 1Russian
State Medical University, Moscow, Russia; 2Russian State Medical University,
Moscow, Moscow, Russia |
|
PNM22 |
SOCIO-ECONOMIC IMPACT OF
PARKINSONS DISEASE ON SPOUSES: THE COMPAS STUDY
Brun - Strang C1, Ziegler M2, 1Novartis-Pharma, Rueil-Malmaison, France;
2Hôpital L. Bellan, Paris, France |
|
PNM23 |
INTERNATIONAL USE OF
HEALTH STATUS QUESTIONNAIRES IN PARKINSON'S DISEASE: TRANSLATION IS NOT
ENOUGH
Hagell P1, McKenna SP2, 1Lund University, Lund, Sweden; 2Galen Research,
Manchester, United Kingdom |
|
PNM24 |
RIVASTIGMINE IS ASSOCIATED
WITH SIGNIFICANTLY LESS CAREGIVER BURDEN THAN DONEPEZIL OR GALANTAMINE
Snyder EH1, McBurney CR1, Thomas S2, Arcona S1, Bolge SC3, 1Novartis
Pharmaceuticals, East Hanover, NJ, USA; 2Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA; 3Consumer Health Sciences, Princeton,
NJ, USA |
|
PNM25 |
DRUG PERSISTENCE PATTERNS
SIMILAR FOR RIVASTIGMINE-TREATED PATIENTS AND DONEPEZIL-TREATED PATIENTS
Mauskopf J1, Paramore C2, Lee WC2, Snyder EH3, 1RTI Health Solutions,
Kansas, NC, USA; 2MEDTAP International, Bethesda, MD, USA; 3Novartis
Pharmaceuticals, East Hanover, NJ, USA |
|
PNM26 |
STANDARD GAMBLE TECHNIQUE
- A TOOL TO ASSESS QUALITY OF LIFE IN PATIENTS WITH EPILEPSY
Dolan P1, Chandler F2, Behrens M2, Baxter C2, 1University of Sheffield,
Sheffield, United Kingdom; 2GlaxoSmithKline, Uxbridge, United Kingdom |
|
PNM27 |
FUNCTIONAL ASSESSMENT OF
MULTIPLE SCLEROSIS (FAMS): EVALUATING THE LINGUISTIC VALIDITY OF 5 NEW
LANGUAGES: PORTUGUESE, JAPANESE, HEBREW, RUSSIAN, AND KOREAN
Eremenco S1, Kaskel P2, de Sa J3, Fukaura H4, Miller A5, Cella D1, 1Evanston
Northwestern Healthcare, Evanston, IL, USA; 2Schering, Berlin, Germany;
3Hospital Santa Maria, Lisbon, Portugal; 4Hokkaido University Hospital,
Sapporo, Japan; 5Carmel Hospital, Haifa, Israel |
| |
|
|
|
|
|
PAIN |
|
|
Pain – Clinical Outcomes
Studies |
|
PPN1 |
TOPIRAMATE FOR THE TREATMENT OF PERIPHERAL
DIABETIC NEUROPATHY: CANADIAN CLINICAL EXPERIENCE
Hwang P1, Brock I2 , 1Janssen-Ortho Inc, Toronto, ON, Canada; 2Research One
International, Lachine, QC, Canada |
|
PPN2 |
TOPIRAMATE IS EFFECTIVE IN PATIENTS WITH PERIPHERAL DIABETIC NEUROPATHY
FOR WHOM OTHER ANTICONVULSANTS HAVE FAILED
Hwang P1, Brock I2 , 1Janssen-Ortho Inc, Toronto, ON, Canada; 2Research One
International, Lachine, QC, Canada |
|
|
Pain – Cost Studies |
|
PPN3 |
A UK MULTI-CENTRE
TRIAL-BASED COST-UTILITY ANALYSIS OF SURGICAL STABILISATION OF THE SPINE VERSUS INTENSIVE REHABILITATION FOR
TREATMENT OF CHRONIC LOW BACK PAIN PATIENTS
Rivero-Arias O1, Campbell H1, Gray A1, Stabilisation Trial S2, 1Oxford
University, Oxford, United Kingdom; 2Nuffield Orthopaedic Centre, Oxford,
United Kingdom |
|
|
Pain – Quality of Life
|
|
PPN4 |
EPIDEMIOLOGY,
CO-MORBIDITY, AND IMPACT ON HEALTH-RELATED QUALITY OF LIFE OF SELF-REPORTED
HEADACHE AND MUSCULOSKELETAL PAIN –
A GENDER PERSPECTIVE
Bingefors C, Isacson D, Uppsala University, Uppsala, Sweden |
|
PPN5 |
ASSESSING PATIENT
SATISFACTION WITH PHARMACOLOGICAL PAIN TREATMENT IN AMBULATORY PRIMARY CARE
PATIENTS
Baró E1, Casado AJ1, García-Cases C2, Clerch L2, Ribas S1, 13D Health
Research, Barcelona, Spain; 2Lácer, S. A, Barcelona, Spain |
|
PPN6 |
CRITICAL PATHWAY STATUS: A
COMPARISON OF PATIENT OUTCOMES
Hanley KN, Peterman AH, Reynolds K, Caprini CA, Evanston Northwestern
Healthcare, Evanston, IL, USA |
|
PPN7 |
THE WILLINGNESS-TO-PAY
APPROACH IN THE COST-BENEFIT ANALYSIS: THE TREATMENT OF PATIENTS AFFECTED
FROM PAINFUL PATHOLOGY
Colombo GL1, Caruggi M2, Muzio A1, 1S.A.V.E. Economic eValuation Analyses
Studies, Milano, Milan, Italy; 2Azienda Ospedaliera di Busto Arsizio, Busto
Arsizio, Varese, Italy |
|
PPN8 |
SUSTAINED-RELEASE TRAMADOL IN CHRONIC PAIN TREATMENT: EFFECTIVENESS AND
INFLUENCE ON QUALITY OF LIFE
López JS1, Barnés E1, Samper D2, Casals M3, Suárez A4, 1Pharma-Consult,
Barcelona, Spain; 2H.U. Trias i Pujol, Spain; 3Fundació Sanitaria d'Igualada,
Barcelona, Spain; 4Zambon, Barcelona, Spain |
|
PPN9 |
CHRONIC PAIN PATIENTS'
SATISFACTION AND QUALITY OF LIFE WITH TRANSDERMAL ANALGESIC MEDICATION
Anderson-Hillemacher A, Hastedt C, Gruenenthal GmbH, Aachen, Germany |
| |
|
|
|
|
|
RESPIRATORY DISEASES/DISORDERS |
|
|
Asthma – Clinical Outcomes Studies |
|
PRP1 |
EPIDEMIOLOGY OF NASAL
POLYPS AND ITS RELATIONSHIP TO ASTHMA
Klossek JM1, Neukirch F2, Pribil C3, Jankowski R4, Serrano E5, Abdelkader
EH3, 1Hôpital Jean Bernard, Nancy, France; 2Faculté de Médecine Xavier
Bichat, Paris, France; 3GSK, Marly le Roy, France; 4Hôpital Central de
Nancy, Nancy, France; 5Hôpital de Rangueil, Toulouse, France |
|
|
Asthma – Cost Studies |
|
PRP2 |
HELIOX IN THE TREATMENT OF STATUS ASTHMATICUS IN THE ICU: A
COST-EFFECTIVENESS ANALYSIS
Tano B1, Hoffmann S2, Pathak D2, 1Ohio State University Medical Center,
Columbus, OH, USA; 2The Ohio State University, Columbus, OH, USA |
|
PRP3 |
LOSSES IN PRODUCTIVITY DUE
TO ASTHMA: A POPULATION BASED ESTIMATE
Mychaskiw MA, Sankaranarayanan J, Purdue University, West Lafayette, IN, USA |
|
PRP4 |
COST-UTILITY OF BECLOMETHASONE-EXTRAFINE (BDP-EF) IN PATIENTS WITH
MODERATE AND SEVERE ASTHMA
Marchetti M1, Cavallo MC2, Annoni E3, Cremonesi G3, 1IRCCS Policlinico
S.Matteo, Pavia, Italy; 2Bocconi University, Milano, Italy; 3Chiesi
Farmaceutici, Parma, Italy |
|
PRP5 |
COST-EFFECTIVENESS OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION
PRODUCT 50/100 MCG TWICE DAILYAND BUDESONIDE 400 MCG TWICE DAILY IN THE
TREATMENTOF ADULTS WITH ASTHMA IN CHINA
Yang L1, Mulligan AT2, 1Fudan University, Shanghai, China; 2GSKChina,
Shanghai, China |
| |
|
|
PRP6 |
COST OF ASTHMA
EXACERBATION IN THE HOSPITAL SETTING IN SPAIN
Borderias Clau L1, Riesco Miranda JA2, Zabaleta Murgiondo MA3, Hernández
Hernández JL4, Pellicer C5, Carrillo Díaz T6, Rodríguez Barrios JM7,
Lumbreras G8, 1Neumology Service San Jorge Hospital, Huesca, Huesca, Spain;
2Neumology Service Virgen del Puerto Hospital, Plasencia, Cáceres, Spain;
3Neumology service Laredo Hospital, Laredo, Cantabria, Spain; 4Neumology
Service Nª Sra. de Sonsoles Hospital, Ávila, Ávila, Spain; 5Neumology
Service, Francesc de Borja Hospital, Gandía, Valencia, Spain; 6Alergy
Service, Dr. Negrín Hospital, Las Palmas de Gran Canaria, Gran Canaria,
Spain; 7GSK Spain, Tres Cantos, Madrid, Spain; 8Villaviciosa de Odón Primary
Health Care Centre, IMSALUD, Villaviciosa de Odón, Madrid, Spain |
|
PRP7 |
A CROSS-SECTIONAL, OBSERVATIONAL STUDY TO ESTABLISH THE RESOURCES AND
COSTS ASSOCIATED WITH CONTROLLED AND POORLY CONTROLLED MODERATE TO SEVERE
ASTHMA PATIENTS IN THE UK
Ossa DF1, Brown R1, Price D2, Everhard F3, 1MEDTAP International, London,
United Kingdom; 2University of Aberdeen, Aberdeen, United Kingdom; 3Novartis
Pharmaceuticals AG, Basel, Switzerland |
|
PRP8 |
THE COST-EFFECTIVENESS OF
DIFFERENT INHALED COMBINATION THERAPIES IN ADULT PATIENTS WITH
MODERATE-TO-SEVERE ASTHMA– A MODELING STUDY FROM HEALTH-CARE PAYER
PERSPECTIVE IN POLAND
Glogowski CA, Gierczynski JM, GlaxoSmithKline Pharmaceuticals S.A, Warsaw,
Poland |
|
PRP9 |
INPATIENT MANAGEMENT OF
ASTHMA IN CHILDREN AND ADOLESCENTS: HOSPITAL RESOURCE USE AND COSTS
O'Brien JA, Pitoniak-Morse CA, Caro JJ, Caro Research Institute, Concord,
MA, USA |
| |
|
|
|
Asthma – Quality of Life Studies |
|
PRP10 |
A RANDOMIZED STUDY
COMPARING THREE HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES IN ASTHMATIC
PATIENTS
Nocea G1, Caloto T2, Hinojosa M3, Prieto L4, Colas C5, Feo F6, 1Merck Sharp
& Dohme, España, Madrid, Spain; 2Merck, Sharp and Dohme, Madrid, Spain;
3Hospital Ramon y Cajal, Madrid, Spain; 4Hospital Universitario Dr. Peset,
Valencia, Spain; 5Hospital Clinico Universitario Lozano Blesa, Zaragoza,
Spain; 6Hospital Alarcos, Ciudad Real, Spain |
|
PRP11 |
THE VALIDITY OF THE WORK
PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE FOR PATIENTS WITH ASTHMA
(WPAI-ASTHMA): RESULTS FROM A
WEB-BASED STUDY
Andreasson E, Svensson K, Berggren F, AstraZeneca R&D Lund, Sweden |
|
PRP12 |
A NEW QUESTIONNAIRE FOR
MEASURING QUALITY OF LIFE (QOL) OF PARENTS OF
CHILDREN WITH ASTHMA
Arpinelli F1, Niero M2, Oprandi N3, 1GSK S.p.A, Verona, Italy; 2University
of Verona, Verona, Italy; 3Emme&erre S.p.A, Padova, Italy |
|
|
COPD – Cost Studies |
|
PRP13 |
COSTS OF COPD IN GERMANY – RESULTS OF A COST-OF ILLNESS STUDY
Spannheimer A1, Schlegel C1, Reitberger U1, Welsch R2, Ruckdaeschel S3,
1Kendle International Inc, Munich, Germany; 2Boehringer Ingelheim Pharma KG,
Ingelheim am Rhein, Germany; 3Pfizer GmbH, Karlsruhe, Germany |
|
PRP14 |
COST OFFSETS FROM
PRESCRIPTION COVERAGE OF AGED PERSONS WITH COPD
Stuart BC1, Doshi J1, Briesacher B1, Wrobel M2, 1University of Maryland
Baltimore, Baltimore, MD, USA; 2Abt Associates, Cambridge, MA, USA |
| |
|
|
|
Respiratory Disorders – Clinical Outcomes Studies |
|
PRP15 |
DO RESPIRATORY DRUGS
REDUCE HOSPITAL ADMISSIONS? AN ECOLOGICAL STUDY CARRIED OUT IN MODENA,
ITALY, TO INVESTIGATE DISTRICTS' VARIABILITY
Maltoni S1, Marata AM1, Brunetti M1, Menna A1, Violante A1, Fellin G2,
Campomori A1, Magrini N1, 1CeVEAS, Modena, Italy; 2AUSL Modena, Modena,
Italy |
|
|
Respiratory Disorders – Cost Studies |
|
PRP16 |
COST-EFFECTIVENESS OF BUPROPION SR IN THE TREATMENT OF TOBACCO
DEPENDENCE
Wcislo J1, Slawik M2, Sas P2, Landa K1, Plisko R1, Glogowski CA3,
Gierczynski JM3, 1HTA Consulting, Krakow, Malopolska, Poland; 2HTA
Consulting, Krakow, Poland; 3GlaxoSmithKline Pharmaceuticals S.A, Warsaw,
Poland |
|
PRP17 |
ESTIMATING HOSPITAL BURDEN
DUE TO PNEUMONIA, ASPIRATION, AND ACUTE LUNG FAILURE: DATA FROM THE NATIONAL
HOSPITAL DISCHARGE SURVEY (NHDS)
Caeser M1, Nichols BR2, Perfetto EM2, 1ALTANA Pharma AG, Konstanz, Germany;
2The Weinberg Group Inc, Washington, DC, USA |
|
|
Respiratory Disorders– Quality of Life Studies |
|
PRP18 |
ANALYSIS OF LONGITUDINAL
CHANGES IN QUALITY OF LIFE BEFORE AND AFTER LUNG TRANSPLANTATION USING A
MULTI-LEVEL MODEL
Post WJ, Vermeulen KM, van der Bij W, Koëter GH, Ten Vergert EM, Groningen
University Hospital, Groningen, The Netherlands |
| |
|
|
|
|
|
SKIN DISORDERS/DISEASES |
|
|
Skin Disorders – Clinical Outcomes Studies |
|
PSN1 |
DERMATOLOGICAL DISEASES
AND PODIATRIC DISORDERS IN THE FEET OF THE ELDERLY POPULATION: A DESCRIPTIVE
STUDY
Balana M1, Martin A2, Novel V3, Guillen F4, Lazaro P5, Diaz JM1, Borras C6,
Macias MD1, Grau C1, 1Novartis Farmaceutica S.A, Barcelona, Spain;
2Instituto de Migraciones y Servicios Sociales, Madrid, Spain; 3Universidad
de Barcelona, Hospitalet de Llobregat, Barcelona, Spain; 4Hospital
Universitario de Getafe, Getafe, Madrid, Spain; 5Hospital General
Universitario Gregorio Marañon, Madrid, Spain; 6Biometrica, Barcelona, Spain |
|
PSN2 |
EFFECTIVITY AND SAFETY OF TACALCITOL IN PSORIASIS VULGARIS IN SPANISH
PATIENTS
Mirada A1, Lecha M2, Barnés E3, López JS4, 1Laboratorios Isdin, Barcelona,
Spain; 2H. Clínic i Provincial de Barcelona, Barcelona, Spain;
3Pharma-Consult, Barcelona, Spain; 4Pharma-Consult, Barcelona, Spain |
|
|
Skin Disorders – Cost Studies |
|
PSN3 |
MANAGEMENT AND SOCIO
ECONOMIC IMPACT OF ATOPIC DERMATITIS (AD) IN
FRANCE : THE ELIPANEL STUDY
Brun - Strang C1, Taïeb A2, 1Novartis-Pharma, Rueil-Malmaison, France;
2Hôpital St André, Bordeaux, France |
|
PSN4 |
ECONOMIC EVALUATION OF TACROLIMUS OINTMENT VERSUS CURRENT CARE IN
MODERATE TO SEVERE ATOPIC DERMATITIS
Moeremans K1, Annemans L2, 1HEDM, Meise, Belgium; 2Ghent University, HEDM,
Meise, Belgium |
|
PSN5 |
THE COST-UTILITY OF CALCIPOTRIOL/BETHAMETHASONE (DOVOBET) OINTMENT IN
THE TREATMENT OF PSORIASIS VULGARIS IN THE UNITED KINGDOM
Noerregaard J1, Lowson D2, 1LEO Pharma, Ballerup, Denmark, Denmark; 2LEO
Pharma, Princes Risborough, Bukinghamshire, United Kingdom |
|
PSN6 |
CHILDREN’S ATOPIC DERMATITIS: PHARMACOECONOMIC COST ANALYSIS
Derkach V1, Prosekova E2, 1Far East Branch of Scientific Research
Institute of Clinic Immunology, Siberian Division of Russi, Vladivostok
Medical University, Vladivostok, Russia; 2Far East Branch of Scientific
Research Institute of Clinic Immunology, Siberian Division of Russian
Academy of Medical Sciences, Vladivostok, Russia |
|
PSN7 |
TREATMENT OF PSORIASIS
WITH CONVENTIONAL SYSTEMIC AGENTS IS ASSOCIATED WITH HIGH MEDICAL COSTS AND
FREQUENT TREATMENT FAILURE
Feldman S1, Evans C2, Russell M3, 1Wake Forest University School of
Medicine, Winston-Salem, NC, USA; 2Mapi Values USA, Boston, MA, USA;
3Biogen, Inc, Cambridge, MA, USA |
|
PSN8 |
COST-OF-ILLNESS STUDY IN
PATIENTS SUFFERING FROM CHRONIC PLAQUE PSORIASIS IN GERMANY
Kugland B1, Ehlken B1, Hofmaier A2, Augustin M3, Berger K4, 1MERG - Medical
Economics Research Group, Munich, Germany; 2Biogen GmbH, Ismaning, Germany;
3University of Freiburg, Freiburg, Germany; 4MERG - Medical Economics
Research Group, Munich, Germany |
| |
|
|
|
Skin Disorders – Quality of Life
|
|
PSN9 |
PREVALENCE AND QUALITY OF
LIFE OF PATIENTS SUFFERING FROM INFLAMMATORY DERMATITIS (PSORIASIS, ECZEMA, ATOPIC DERMATITIS AND URTICARIA) IN FRANCE -
INSTANT STUDY
Wolkenstein P1, Crochard A2, Mimaud V3, Stalder JF4, Lorette G5, El Hasnaoui
A6, 1Henri Mondor Hospital, Créteil, France; 2GlaxoSmithKline, Marly Le Roy,
France; 3CEMKA, Bourg la Reine, France; 4Hôtel Dieu Hospital, Nantes,
France; 5Trousseau Hospital, Tours, France; 6Laboratory GSK, Marly Le Roy,
France |
|
PSN10 |
THE USE OF DISCRETE CHOICE
ANALYSIS TO ASSIST WITH THE INTERPRETATION OF QUALITY OF LIFE SCORES
Backhouse ME1, Meads D2, Doward LC2, McKenna SP2, 1Novartis Pharma AG,
Basel, Switzerland; 2Galen Research, Manchester, United Kingdom |
|
PSN11 |
THE WILLINGNESS-TO-PAY FOR
PSORIASIS TREATMENT IN DENMARK
Hart-Hansen K1, Kjaer T2, Noerregaard J3, 1The Royal Veterinary and
Agricultural University, Frederiksberg C, Denmark, Denmark; 2University of
Southern Denmark, Odense C, Denmark, Denmark; 3LEO Pharma, Ballerup, Denmark |
|
PSN12 |
QUALITY-OF-LIFE IN
PATIENTS SUFFERING FROM ATOPIC DERMATITIS IN
GERMANY
Ehlken B1, Kugland B1, Schramm B1, Quednau K2, Berger K1, 1MERG - Medical
Economics Research Group, Munich, Germany; 2Novartis Pharma GmbH, Nuremberg,
Germany |
|
PSN13 |
COSTEFFECTIVENESS OF ALEFACEPT IN PATIENTS WITH MODERATE TO SEVERE
PSORIASIS
Jorstad IC, Haugli K, Eggen E, Kristiansen IS, University of Tromso, Tromso,
Norway |
|
PSN14 |
QUALITY OF LIFE IN
PATIENTS SUFFERING FROM PSORIASIS VULGARIS IN
GERMANY – A NON-INTERVENTIONAL SURVEY
Berger K1, Ehlken B1, Kugland B1, Hofmaier A2, Augustin M3, 1MERG - Medical
Economics Research Group, Munich, Germany; 2Biogen GmbH, Ismaning, Germany;
3University of Freiburg, Freiburg, Germany |
| |
|
|
PSN15 |
DURATION OF PSORIASIS AND
QUALITY OF LIFE
Taïeb C, Marionneau N, Myon E, Pharmaco Economics & Quality of Life
Department, Boulogne Billancourt, France |
|
PSN16 |
PSORIASIS: IMPACT OF THE
TREATMENT ON QUALITY OF LIFE
Myon E, Taïeb C, Pharmaco Economics & Quality of Life Department, Boulogne
Billancourt, France |
|
PSN17 |
PSORIASIS AND QUALITY OF
LIFE SPANISH RESULTS
Taïeb C, Marionneau N, Myon E, Pharmaco Economics & Quality of Life
Department, Boulogne Billancourt, France |
|
PSN18 |
PSORIASIS: QUALITY OF LIFE
ACCORDING TO GENDER
Taïeb C, Marionneau N, Myon E, Pharmaco Economics & Quality of Life
Department, Boulogne Billancourt, France |
|
PSN19 |
DERMATOSIS AND DEPRESSIVE SYMPTOMATOLOGY: FRENCH RESULTS
Dehen L1, Dubertret L1, Aube I2, Myon E3, Taïeb C3, 1Hôpital St Louis,
Boulogne Billancourt, France; 2Pierre Fabre Dermatologie, Boulogne
Billancourt, France; 3Pharmaco Economics & Quality of Life Department,
Boulogne Billancourt, France |
|
PSN20 |
QUALITY OF LIFE AND
PSORIASIS. IMPACT OF TACALCITOL TREATMENT IN
SPANISH POPULATION
Barnés E1, Mirada A2, Lecha M3, López JS4, 1Pharma-Consult, Barcelona,
Spain; 2Laboratorios Isdin, Barcelona, Spain; 3H. Clínic i Provincial de
Barcelona, Barcelona, Spain; 4Pharma-Consult, Barcelona, Saipan |
| |
|
|
|
|
|
METHODOLOGICAL ISSUES |
|
|
Methodological Issues – Compliance Studies |
|
PMD1 |
PROPERLY ADDRESSING
TIME-DEPENDENCE WHEN ANALYZING THE IMPACT OF COMPLIANCE WITH MEDICATION IN
CHRONIC ILLNESSES
Ishak KJ1, Caro JJ2, Huybrechts KF2, Naujoks C3, 1Caro Research, Dorval,
Quebec, Canada; 2Caro Research Institute, Concord, MA, USA; 3Novartis,
Nuremberg, Germany |
|
|
Methodological Issues – Clinical Outcomes Studies |
|
PMD2 |
DISABILITY IN STROKE
OUTCOMES RESEARCH: CLINICAL MEANING OF THE BARTHEL
INDEX, THE FUNCTIONAL INDEPENDENCE MEASURE AND THE MODIFIED RANKIN SCALE
Kwon S1, Hartzema AG1, Duncan PW1, Lai SM2, 1University of Florida,
Gainesville, FL, USA; 2University of Kansas, Kansas City, KS, USA |
|
PMD3 |
OUTCOMES OF AN INTERVENTION TO
IMPROVE HOSPITAL ANTIBIOTIC PRESCRIBING: INTERRUPTED TIME SERIES ANALYSIS
WITH SEGMENTED REGRESSION
Ansari F1, Gray K1, Nathwani D1, Phillips G1, Ogston S1, Ramsay C2, Davey
P1, 1University of Dundee, Dundee, United Kingdom; 2University of Aberdeen,
Aberdeen, United Kingdom |
|
PMD4 |
DIFFERENCES IN PATIENT
BURDEN BETWEEN ENDOANAL MRI, DEFECOGRAPHY AND
ANORECTAL FUNCTIONAL TESTING FOR PATIENTS WITH FAECAL INCONTINENCE
Deutekom M, Dijkgraaf MGW, Bossuyt PM, Terra MP, Dobben AC,Stoker J,Academic
Medical Center, Amsterdam,The Netherlands |
|
PMD5 |
A METHOD FOR
IDENTIFICATION OF FRONTIER PRACTICE IN DIABETES CARE
Christensen MC1, Binder C2, Hansen JB2, Lyholm B2, Remler DK1, 1Columbia
University, New York,NY, USA; 2Novo Nordisk A/S,Virum,Denmark |
|
PMD6 |
DEVELOPMENT OF A WEB-BASED
SURVEY TO DETERMINE PRACTICE PATTERNS FOR TREATMENT OF ADVANCED STAGE BREAST
CANCER IN FIVE EUROPEAN COUNTRIES
Ramsey SD1, Clarke L2, Donato B3, Sullivan SD4, Varela C3, Hermans
N3, Boudreau D4, 1Fred Hutchinson Cancer Research Center, Seattle, WA,USA;
2Cornerstone Systems Northwest, Lynden, WA,USA; 3Bristol-Myers Squibb
Company, Wallingford,CT, USA; 4University of Washington,Seattle, WA,USA
|
| |
|
|
PMD7 |
DATA ACQUISITION AND
INTEGRATION FOR ANTIBIOTIC TREATMENT REPORTING
Haase M1, Sasaki P1, Fazio J2, 1Strong Square,LLC,Kirkland, WA,USA;
2Northwest Pharmacy Services, Portland,OR, USA |
|
PMD8 |
PREDICTORS OF ANTIBIOTIC
PRESCRIBING FOR UPPER RESPIRATORY INFECTIONS IN AN AMBULATORY POPULATION
Dickson M1, Gibson J2, Kotchmar G1, 1University of South
Carolina,Columbia,SC,USA; 2SC Dept of Health & Environmental
Control,Columbia,SC,USA |
|
PMD9 |
OPTIMIZATION OF AIDS PILOT
CLINICAL TRIAL USING LEAMSIM
Monleon T1, Ocanña J1, Vegas E2, Fonseca P3, Abbas I3, Casanovas J3,
Cobo E3, Arnaiz JA4, Carné X4, Gatell JM4, 1University of
Barcelona,Barcelona, SC,Spain; 2University of Barcelona, Barcelona,Spain;
3UPC,Barcelona,Spain; 4Hospital Clinic,Barcelona, Spain |
|
PMD10 |
GENETIC TESTING,PREDICTIVE
GENETIC TESTING FOR HEREDITARY CANCER
Jonas S, Wild C, Schamberger C, Austrian Academy of Sciences, Vienna,
MS, Austria |
|
PMD11 |
SELF-REPORTED PATIENT
EXPERIENCE DATA,PROVIDED TO PHYSICIANS AT THE POINT-OF-CARE,OFFER AN
IMPORTANT COMPLEMENT TO TRADITIONAL EFFICACY DATA AND ENABLE THE DERIVATION
OF PRACTICE-WIDE TREATMENT GUIDELINES
Schmeichel CJ1, Netherton DR2, 1SMA,Munster, IN,USA; 2InfoMedics
International,Inc, Woburn,MA,USA |
| |
|
|
|
Methodological Issues – Cost
Studies |
|
PMD12 |
COST SOURCE AND
PERSPECTIVE IN ECONOMIC OUTCOMES STUDIES: FOCUS ON POSTERS PRESENTED AT THE
7TH ANNUAL INTERNATIONAL ISPOR MEETING
Kwon S, Taylor MD, Mayhew D, Hartzema AG, University of Florida,
Gainesville, FL, USA |
|
PMD14 |
WILLINGNESS TO PAY,
WILLINGNESS TO WAIT, AND SUPER QALYS: NARROWING THE CONCEPTUAL GAP BETWEEN
CARDINAL AND ORDINAL HEALTH UTILITY MEASURES
Johnson FR1, Hauber AB2, Mauskopf J1, 1Research Triangle Institute,
Research Triangle Park, NC, USA; 2Research Triangle Institute, Hatboro, PA,
USA |
|
PMD15 |
THE INTERNATIONAL COSTING
SOURCES DATABASE: A TOOL FOR ENSURING CONSISTENT AND RIGOROUS INTERNATIONAL
COSTING
Germe M1, Baron-Papillon F1, Ryan J2, De Peuter R3, 1Mapi Values,
Lyon, France; 2Mapi Values UK, Macclesfield, Cheshire, United Kingdom; 3Mapi
Values, Houten, The Netherland |
|
PMD16 |
UNCERTAINTY AND VALUE OF
INFORMATION IN RAPID ECONOMIC EVALUATIONS
Gonzalez-Perez JG, University of Aberdeen, Aberdeen, United Kingdom |
|
PMD17 |
PROTOCOL FOR
MEDICOECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF INFANTILE
BRONCHIOLITIS
Trichard M, Chaufferin G,Laboratoires BOIRON,Sainte-Foy-Lès-Lyon,
France |
|
PMD18 |
INDIRECT COSTS OF A
LARGE-SCALE IMMUNIZATION PROGRAM – WHEN COSTS EXCEED SAVINGS
Welte R1, van den Dobbelsteen G2, Postma MJ3, 1University of Ulm, Ulm,
Germany; 2National Institute of Public Health and the Environment, Bilthoven,
The Netherlands; 2Groningen University Institute for Drug
Exploration/University of Groningen Research Institute of Pharmacy
(GUIDE/GRIP), Groningen, The Netherlands |
| |
|
|
PMD19 |
THE COST-EFFECTIVENESS OF
TREATMENT FOR TYPE 1 DIABETES
Budhiarso I1, Gonzalez-Vizoso R1, Martin ML1, Bushnell DM1, Mingliang
Z2, 1Health Research Associates,Inc,Mountlake Terrace, WA,USA; 2Johnson &
Johnson, Raritan, NJ,USA |
|
PMD20 |
THE COST-EFFECTIVENESS OF
SCREENING PROGRAMS USING SINGLE AND MULTIPLE BIRTH COHORT SIMULATIONS: A
COMPARISON USING A MODEL OF CERVICAL CANCER
Dewilde S1, Anderson R2, 1MEDTAP International, London, United
Kingdom; 2CHERE, University of Technology, Sydney, Australia |
|
PMD21 |
LIFE EXPECTANCY AND THE
DISCOUNTING OF HEALTH OUTCOMES
Stant A, Groen H, Post W, TenVergert E, University Hospital
Groningen, Groningen, The Netherlands |
|
PMD22 |
EPIDEMIOLOGY AND
PHARMAECONOMY OF COPD ACROSS EUROPE
Sandtmann R1, Nowak D2, Schramm B3, Kilgert K3, Berger K3, 1ALTANA
Pharma, Konstanz,Germany; 2Ludwig-Maximilians-University, München,Germany;
3MERGMedical Economics Research Group, München, Germany |
|
PMD23 |
IDENTIFICATION OF UNIT
COSTS IN RHEUMATOID ARTHRITIS - RESEARCH APPROACH AND RESULTS
Rosery H, Schwander B,Bergemann R, Institute for Medical Outcome Research,
Loerrach, Germany |
|
PMD24 |
FIRST EXPERIENCES WITH THE
CONDUCTION OF RAPID HEALTH ECONOMIC HEALTH TECHNOLOGY ASSESSMENTS
Aidelsburger P1, Hessel FP2, Felder S3, Wasem J2, 1University of
Greifswald, Greifswald, Germany; 2University Duisburg-Essen,Essen, Germany;
3University Clinic, ISMHE, Magdeburg,Germany |
|
PMD25 |
THE TIME INCONSISTENCY OF
DECISIONS IN PHARMACOECONOMIC SEQUENTIAL DECISION PROBLEMS
Jakubczyk MK1, Kowalik E1, Niewada MP2, 1Warsaw School of Economics,
Warsaw, Poland; 2Medical University of Warsaw, Warsaw, Poland |
|
PMD26 |
COST-ASSESSMENT
RE-CONSIDERED: THE CASE OF HIP FRACTURE
Brock EM, University of St Andrews,St Andrews,Scotland,United Kingdom
|
| |
|
|
|
Methodological Issues –
Modeling |
|
PMD28 |
CHALLENGES FOR MODEL-BASED
ECONOMIC EVALUATIONS OF GLAUCOMA AND OCULAR HYPERTENSION TREATMENTS
Althin R1, Dhawan R2, Grima D3, Bernard L3, 1Pharmacia Limited, High
Wycombe, Bucks, United Kingdom; 2Pharmacia Corporation, Peapack, NJ, USA;
3Innovus Research Inc,Burlington,ON,Canada |
|
PMD29 |
A MULTI-OUTCOME DECISION
MODEL FOR PARKINSON'S DISEASE
Siebert U1, Bornschein B2, Sroczynski G1, Spottke A3, Dodel R3,
1Harvard University, Boston, MA, USA; 2University of Munich, Munich,
Germany; 3University of Bonn, Bonn, Germany |
|
PMD30 |
MODELLING OF PREVALENCE, COSTS AND OUTCOME OF
ACID-RELATED DISORDERS USING CLAIMS DATA
Höer A1, Gothe H1, von Zahn J1, Glaeske G2, Häussler B1, 1IGES
Institut für Gesundheits- und Sozialforschung, Berlin, Germany; 2Universität
Bremen, Bremen, Germany |
|
PMD31 |
DECISION-ANALYTIC MODELING
IN PARKINSON'S DISEASE
Siebert U1, Bornschein B2, Walbert T3, Dodel R3, 1Harvard University,
Boston,MA,USA; 2University of Munich,Munich,Germany; 3University of
Bonn,Bonn,Germany |
|
PMD32 |
ENSURING A STANDARD USER
INTERFACE FOR MODELS: MODEL-IT
Caro JJ, Magno LL,Caro Research Institute,Concord,MA, USA |
|
PMD33 |
WITHDRAWN |
|
PMD34 |
ANALYTIC CHOICES IN
ECONOMIC MODELS OF TREATMENTS FOR RHEUMATOID ARTHRITIS: WHAT MAKES A
DIFFERENCE?
Barbieri M1, Drummond M1, Wong J2, 1Innovus Research UK Ltd,High
Wycombe,United Kingdom; 2New England Medical Center, Boston,MA, USA |
|
PMD35 |
A METHODOLOGICAL APPROACH
TO ASSESS COST DUE TO DYING IN THE CONTEXT OF DECISION ANALYTIC MODELLING
Aidelsburger P1, Wasem J2, 1University of Greifswald, Greifswald,
Germany; 2University Duisburg-Essen, Essen, Germany |
| |
|
|
|
Methodological Issues – Other
Studies |
|
PMD36 |
ARE ISPOR SHORT COURSES A
COST-EFFECTIVE WAY OF EDUCATING PARTICIPANTS AND ENHANCING MEETING
ATTENDANCE?
Basskin LE1, Augustyniak L2, 1Trinka Medical Publications, Cooper
City, FL, USA; 2ISPOR, Lawrenceville, NJ,USA |
|
|
Methodological Issues –
Quality of Life Studies |
|
PMD37 |
RECOMMENDATIONS TO THE
EUROPEAN REGULATORS FOR THE CROSS-CULTURAL ADAPTATION OF PRO MEASURES
Conway K,Mear I, Acquadro C, Mapi Research Institute, Lyon, France
|
|
PMD38 |
WORST AND BEST EYE VISUAL
ACUITY CONSEQUENCES ON VISION-RELATED QUALITY OF LIFE IN PATIENTS SUFFERING
FROM AGE RELATED MACULAR DEGENERATION
Nordmann J1, Berdeaux G2, 1Quinze-Vingts Centre Hospitalier National
d'Ophtalmologie, Paris, France; 2Alcon,Rueil-Malmaison, France |
|
PMD39 |
DESCRIPTION OF THE
PRINCIPLES OF GOOD PRACTICE FOR TRANSLATION AND CULTURAL ADAPTATION OF PRO
MEASURES: ISPOR QOLSIG GROUP
Wild DJ1, Ford S2, Martin M3, Eremenco S4, Verjee-lorenz A1, 1Oxford
Outcomes Ltd, Cassington, Oxford, United Kingdom; 2Pfizer Global
Pharmaceuticals, Kalamazoo,MI, USA; 3Health Research Associates, Inc (HRA),
Seattle, WA,USA; 4Evanston Northwestern Healthcare, Evanston,IL,USA |
|
PMD40 |
UTILISATION OF THE FOCUS
GROUP TECHNIQUE IN THE DEVELOPMENT OF QUALITY OF LIFE QUESTIONNAIRES
Barea N1, Garcia S1, Perulero N1, Sarmiento M1, Badia X2, 1HOTrials
(Health Outcomes Research Europe Group), Barcelona, Spain; 2Health Outcomes
Research Europe Group, Barcelona, Spain |
|
PMD41 |
THE NATURE OF THE
QUALITY-ADJUSTED LIFE YEAR (QALY) CALCULATION
Prieto L1, Sacristan JA2, 1Eli Lilly & Co, Alcobendas, Madrid, Spain;
2Eli Lilly & Co., Spain, Alcobendas, Madrid, Spain |
|
PMD42 |
LINGUISTIC VALIDATION OF
THE QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE (Q-LES-Q) IN 24
LANGUAGES
Mear I1, Conway K1, Touzet L1, Endicott J2, O'Leary M3, 1Mapi
Research Institute, Lyon, France; 2New York State Psychiatric Institute,New
York,NY, USA; 3GlaxoSmithKline, Brentford, Middlesex,United Kingdom |
|
PMD43 |
BENEFITS OF
TRANSLATABILITY ASSESSMENT TO ENHANCE THE COHERENCE OF DATA IN INTERNATIONAL
STUDIES – THE IQOD EXPERIENCE
Lobo Luppi L1, Conway K2, Mear I2, Martin M3, Ware J3, 1for IQOD
Group, Lyon, France; 2Mapi Research Institute, Lyon, France; 3Quality
Metric,Inc,Lincoln,RI,USA |
| |
|
|
|
Methodological Issues – Risk
Assessment Studies |
|
PMD44 |
ADVANCING RISK ADJUSTMENT
FOR SCHIZOPHRENIA
Martin BC, Dorfman JH, Miller LS, Kotzan JA, University of Georgia,
Athens, GA, USA |
|
PMD45 |
OUTCOMES RESEARCH AND
PHASE 1-2 PHARMACEUTICAL RISK ASSESSMENT
Lockett AE, Covance, Leeds, United Kingdom |
|
PMD46 |
PROCESS UTILITY DERIVED
FROM PROVIDING INFORMAL CARE
Brouwer W1, Van Exel J2, Van den Berg B2, Koopmanschap M1, 1Erasmus
University Rotterdam, Rotterdam, The Netherlands; 2Erasmus Medical Centre
Rotterdam, Rotterdam,The Netherlands |
|
|
Methodological Issues –
Utility Studies |
|
PMD47 |
CALCULATING UTILITY VALUES
FROM SF-36: A COMPARISON OF DIFFERENT ALGORITHMS
Svensson K, AstraZeneca R&D Lund, Sweden, Lund, Sweden |
|
PMD48 |
RELATIVE WEIGHTS ASSIGNED
TO DRUGS AND BIOLOGICALS: OPPS METHODS AND CONCEPTS
Baker JJ, University of Rochester, Pickton,TX,USA |
| |
|
|
